Literature DB >> 18451139

Epigenetic modification of CCAAT/enhancer binding protein alpha expression in acute myeloid leukemia.

Björn Hackanson1, Kristi L Bennett, Romulo M Brena, Jinmai Jiang, Rainer Claus, Shih-Shih Chen, Nadya Blagitko-Dorfs, Katie Maharry, Susan P Whitman, Thomas D Schmittgen, Michael Lübbert, Guido Marcucci, Clara D Bloomfield, Christoph Plass.   

Abstract

Functional loss of CCAAT/enhancer binding protein alpha (C/EBP alpha), a master regulatory transcription factor in the hematopoietic system, can result in a differentiation block in granulopoiesis and thus contribute to leukemic transformation. Here, we show the effect of epigenetic aberrations in regulating C/EBP alpha expression in acute myeloid leukemia (AML). Comprehensive DNA methylation analyses of the CpG island of C/EBP alpha identified a densely methylated upstream promoter region in 51% of AML patients. Aberrant DNA methylation was strongly associated with two generally prognostically favorable cytogenetic subgroups: inv(16) and t(15;17). Surprisingly, while epigenetic treatment increased C/EBP alpha mRNA levels in vitro, C/EBP alpha protein levels decreased. Using a computational microRNA (miRNA) prediction approach and functional studies, we show that C/EBP alpha mRNA is a target for miRNA-124a. This miRNA is frequently silenced by epigenetic mechanisms in leukemia cell lines, becomes up-regulated after epigenetic treatment, and targets the C/EBP alpha 3' untranslated region. In this way, C/EBP alpha protein expression is reduced in a posttranscriptional manner. Our results indicate that epigenetic alterations of C/EBP alpha are a frequent event in AML and that epigenetic treatment can result in down-regulation of a key hematopoietic transcription factor.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18451139     DOI: 10.1158/0008-5472.CAN-08-0483

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  54 in total

Review 1.  Smad-mediated regulation of microRNA biosynthesis.

Authors:  Matthew T Blahna; Akiko Hata
Journal:  FEBS Lett       Date:  2012-01-28       Impact factor: 4.124

2.  XXIII International Association for Comparative Research on Leukemia and Related Diseases Symposium: from molecular pathogenesis to targeted therapy in leukemia and solid tumors.

Authors:  Björn Hackanson; Heiko Becker; Tobias Berg; Mascha Binder; Christine Dierks; Jesús Duque-Afonso; Michael D Lairmore; Henning S Schäfer; Marc Schnitzler; Robert Zeiser; Uwe Martens; Roland Mertelsmann; Michael Lübbert
Journal:  Cancer Res       Date:  2008-07-15       Impact factor: 12.701

3.  MiR-182 is up-regulated and targeting Cebpa in hepatocellular carcinoma.

Authors:  Chenggang Wang; Ren Ren; Haolin Hu; Changjun Tan; Miao Han; Xiaolin Wang; Yun Zheng
Journal:  Chin J Cancer Res       Date:  2014-02       Impact factor: 5.087

Review 4.  The prognostic and functional role of microRNAs in acute myeloid leukemia.

Authors:  Guido Marcucci; Krzysztof Mrózek; Michael D Radmacher; Ramiro Garzon; Clara D Bloomfield
Journal:  Blood       Date:  2010-11-02       Impact factor: 22.113

5.  DNA methylation protects hematopoietic stem cell multipotency from myeloerythroid restriction.

Authors:  Ann-Marie Bröske; Lena Vockentanz; Shabnam Kharazi; Matthew R Huska; Elena Mancini; Marina Scheller; Christiane Kuhl; Andreas Enns; Marco Prinz; Rudolf Jaenisch; Claus Nerlov; Achim Leutz; Miguel A Andrade-Navarro; Sten Eirik W Jacobsen; Frank Rosenbauer
Journal:  Nat Genet       Date:  2009-10-04       Impact factor: 38.330

6.  Targeting Smad4 links microRNA-146a to the TGF-beta pathway during retinoid acid induction in acute promyelocytic leukemia cell line.

Authors:  Hua Zhong; Hai-rong Wang; Shuang Yang; Ji-hua Zhong; Ting Wang; Chun Wang; Fang-yuan Chen
Journal:  Int J Hematol       Date:  2010-06-25       Impact factor: 2.490

Review 7.  Genetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia.

Authors:  Margaret L Gulley; Thomas C Shea; Yuri Fedoriw
Journal:  J Mol Diagn       Date:  2009-12-03       Impact factor: 5.568

8.  In vivo deficiency of both C/EBPβ and C/EBPε results in highly defective myeloid differentiation and lack of cytokine response.

Authors:  Tadayuki Akagi; Nils H Thoennissen; Ann George; Gay Crooks; Jee Hoon Song; Ryoko Okamoto; Daniel Nowak; Adrian F Gombart; H Phillip Koeffler
Journal:  PLoS One       Date:  2010-11-03       Impact factor: 3.240

Review 9.  Advances in understanding benzene health effects and susceptibility.

Authors:  Martyn T Smith
Journal:  Annu Rev Public Health       Date:  2010       Impact factor: 21.981

10.  Methylation status of DDIT3 gene in chronic myeloid leukemia.

Authors:  Ya-li Wang; Jun Qian; Jiang Lin; Dong-ming Yao; Zhen Qian; Zhao-hui Zhu; Jian-yong Li
Journal:  J Exp Clin Cancer Res       Date:  2010-05-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.